Why is the ResMed share price climbing today?

ResMed shares are trading ex-dividend.

| More on:

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • ResMed shares push 1.40% higher to $28.25 
  • The company's shares are trading ex-dividend today 
  • ResMed is set to pay its latest quarterly dividend to eligible shareholders on 16 June 

The ResMed Inc (ASX: RMD) share price is heading north during early Wednesday morning.

At the time of writing, the sleep treatment focused medical device company's shares are up 1.40% to $28.25.

Why are ResMed shares edging higher today? 

Following the company's third quarter results released on 29 April, investors are eyeing ResMed shares as they go ex-dividend today.

While typically a company's shares travel lower on the ex-dividend date, this hasn't been the case this morning. This is because of the heavy losses ResMed has recorded in the past few weeks, hitting an 11-month low of $27.51 yesterday.

It appears that bargain hunters are swooping in to take advantage of the recent share price weakness.

What does this mean for ResMed shareholders?

For those eligible for ResMed's quarterly dividend, shareholders will receive a payment of US 4.2 cents per share on 16 June. The dividend is unfranked, which means investors will unfortunately miss out on the tax credits.

The latest dividend reflects a 7.69% increase when compared to the prior corresponding period (US 3.9 cents per share).

In case you were wondering, the company does not have a dividend reinvestment plan (DRP).

Are ResMed shares a buy now?

Following the company's financial scorecard, a couple of brokers weighed in on the ResMed share price.

The team at Goldman Sachs cut its 12-month price target by 6% to $33.70 for the healthcare company's shares. Its analysts believe that there is still more upside in ResMed shares despite missing its performance targets recently.

Based on the current share price, this implies an upside of about 19% for investors.

Furthermore, Macquarie also slashed its rating on ResMed shares by 2.7% to $36.50 a pop. This also implies an upside of around 29% from where the company trades today.

ResMed share price summary

Over the past 12 months, ResMed shares have gained 14% on the back of positive investor sentiment. On the other hand, the S&P/ASX 200 Index (ASX: XJO) has fallen by 1% over the same timeframe.

ResMed shares reached a 52-week high of $40.49 in August, before backtracking amid inflationary movements and soaring living costs.

Based on today's price, ResMed commands a market capitalisation of roughly $11.41 billion and has a trailing dividend yield of 0.56%.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »